5 Risky Small-Cap Biotech Stocks to Buy Next Month

Looking to add a few thrills to your investing portfolio? Small-cap biotech stocks should be a good place to start. They come with significant risks, but the potential rewards are great. Here's why Celldex Therapeutics, Geron, Halozyme Therapeutics , Lexicon Pharmaceuticals, and Synergy Pharmaceuticals are among the best small-cap biotech stocks to buy in February.

Celldex: Rising from the ashes

Celldex was severely wounded after its experimental brain cancer drug Rintega failed in a late-stage clinical study. However, the small biotech was only down, not out. Celldex's pipeline includes five other candidates.

Back to news